Table 1. Randomized trials and meta-analyses of adjuvant chemotherapy in NSCLC.

Study name	Study type	Setting	Number of patients	Disease stage	Drug(s)	P value/HR (95% CI)	5-year survival advantage, %
BMJ 1995	Meta-analysis	Adjuvant	1,394	I–IIIA	CDDP based	0.08/0.87 (0.74–1.02)	5
IALT	Phase III	Adjuvant	1,867	I–III	CDDP-VA	<0.03/0.86 (0.76–0.98)	4.1
JBR.10	Phase III	Adjuvant	482	IB–II	CDDP-VNB	0.001/0.69 (0.52–0.91)	15
CALGB 9633	Phase III	Adjuvant	344	IB	CBDCA-PTX	0.32/NS	3
ANITA	Phase III	Adjuvant	840	IB–IIIA	CDDP-VNB	0.017/0.8 (0.66–0.96)	8.4
LACE	Meta-analysis	Adjuvant	4,584	I–III	CDDP-based	0.005/0.89 (0.82–0.96)	5.4
WJSG (II)	Phase III	Adjuvant	323	I–III	UFT	0.022/0.55 (0.36–0.86)	15
JLCRG	Phase III	Adjuvant	979	I	UFT	0.04/0.71 (0.52–0.98)	3

NSCLC, non-small cell lung cancer; ANITA, Adjuvant Navelbine International Adjuvant Lung Cancer Collaborative Group Trial; BLT, Big Lung Trial; BMJ, British Medical Journal; CALGB, Cancer and Leukemia Group B; CBDCA, carboplatin; CDDP, cisplatin; CI, confidence interval; CT, chemotherapy; HR, hazard ratio; IALT, International Adjuvant Lung Cancer Collaborative Group Trial; LACE, Lung Adjuvant Cisplatin Evaluation; NS, not stated; PTX, paclitaxel; UFT, tegafur uracil; VA, vinca alkaloid; VNB, vinorelbine; WJSG, West Japan Study Group for Lung Cancer Surgery; NSCLC, non-small cell lung cancer.